Serum level of vascular endothelial growth factor (VEGF) as an independent prognostic factor in metastatic renal cell carcinoma (MRCC)

被引：0
|
作者：
Negrier, S.
Chabaud, S.
Escudier, B.
Ravaud, A.
Chevreau, C.
Blay, J. Y.
Delva, R.
Biota, C.
Perol, D.
Menetrier-Caux, C.
机构：
[1] Ctr Leon Berard, Lyon, France
[2] Inst Gustave Roussy, Villejuif, France
[3] CHU Bordeaux, Bordeaux, France
[4] Ctr Claudius Regaud, Toulouse, France
[5] Hop Edouard Herriot, Lyon, France
[6] INSERM 590, Lyon, France
[7] Ctr Paul Papin, Angers, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5044
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Increased serum levels of vascular endothelial growth factor in patients with renal cell carcinoma
    Sato, K
    Tsuchiya, N
    Sasaki, R
    Shimoda, N
    Satoh, S
    Ogawa, O
    Kato, T
    [J]. JAPANESE JOURNAL OF CANCER RESEARCH, 1999, 90 (08): : 874 - 879
  • [32] Conditional survival (CS) for patients with metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor (VEGF)-targeted therapy (TT): Results from the International mRCC Database Consortium.
    Choueiri, Toni K.
    Xie, Wanling
    Harshman, Lauren Christine
    Bjarnason, Georg A.
    Knox, Jennifer J.
    MacKenzie, Mary J.
    Wood, Lori
    Vaishampayan, Ulka N.
    Tan, Min-Han
    Rha, Sun Young
    Donskov, Frede
    Agarwal, Neeraj
    Kollmannsberger, Christian K.
    North, Scott A.
    Rini, Brian I.
    Heng, Daniel Yick Chin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [33] Expression analysis of the vascular endothelial growth factor (VEGF) family in renal cell carcinoma: Targeting the VEGF pathway
    Lam, JS
    Leppert, JT
    Yu, H
    Seligson, DB
    Dong, J
    Horvath, S
    Pantuck, AJ
    Figlin, RA
    Belldegrun, AS
    [J]. JOURNAL OF UROLOGY, 2006, 175 (04): : 122 - 122
  • [34] Targeting Vascular Endothelial Growth Factor in Renal Cell Carcinoma
    Patel, Nilay S.
    Muneer, Asif
    Blick, Christopher
    Arya, Manit
    Harris, Adrian L.
    [J]. TUMOR BIOLOGY, 2009, 30 (5-6) : 292 - 299
  • [35] Incidence and severity of hypothyroidism and survival outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs).
    Bailey, Erin B.
    Tantravahi, Srinivas Kiran
    Wells, Chesley E.
    Straubhar, Alli M.
    Batten, Julia A.
    Poole, Austin
    Stenehjem, David D.
    Agarwal, Neeraj
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [36] Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma
    Y Yokoyama
    D S Charnock-Jones
    D Licence
    A Yanaihara
    J M Hastings
    C M Holland
    M Emoto
    M Umemoto
    T Sakamoto
    S Sato
    H Mizunuma
    S K Smith
    [J]. British Journal of Cancer, 2003, 88 : 237 - 244
  • [37] Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma
    Yokoyama, Y
    Charnock-Jones, DS
    Licence, D
    Yanaihara, A
    Hastings, JM
    Holland, CM
    Emoto, M
    Umemoto, M
    Sakamoto, T
    Sato, S
    Mizunuma, H
    Smith, SK
    [J]. BRITISH JOURNAL OF CANCER, 2003, 88 (02) : 237 - 244
  • [38] Establishment of the classifier for a response to vascular endothelial growth factor (VEGF)-tyrosine kinase inhibitor (TKI) in metastatic renal cell carcinoma
    Go, Heounjeong
    Kang, Mun Jung
    Kim, Pil-Jong
    Park, Ja-Min
    Lee, Jae-Lyun
    Park, Ji Young
    Cho, Yong Mee
    [J]. CANCER RESEARCH, 2016, 76
  • [39] SERUM THYMIDINE KINASE AND VASCULAR EN DOTHELIAL GROWTH FACTOR (VEGF) IN RENAL CELL CARCINOMA
    Nisman, B.
    Nechushtan, H.
    Yutkin, V.
    Peretz, T.
    Gronowitz, S.
    Pode, D.
    [J]. TUMOR BIOLOGY, 2010, 31 : S64 - S65
  • [40] Serum basic fibroblast growth factor and vascular endothelial growth factor in metastatic renal cell carcinoma treated with interferon alfa-2b
    Vermeulen, PB
    Dirix, LY
    Martin, M
    Lemmens, J
    VanOosterom, AT
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (17) : 1316 - 1317
12345